Clinical Trials Directory

Trials / Completed

CompletedNCT00057434

Vitamin A Therapy for Tuberculosis

Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,140 (planned)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) · NIH
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The study will determine whether a daily vitamin and mineral supplement (a multivitamin including Vitamin A) will improve health when added to standard chemotherapy for tuberculosis. This study will compare the effectiveness of the multivitamin in HIV infected and HIV uninfected patients.

Detailed description

By the year 2000, 13.8 % of individuals with HIV will be co-infected with tuberculosis (TB). Despite effective TB chemotherapy, mortality rates remain extremely high, and no simple, inexpensive intervention is available. Prior to the discovery of antibiotic treatment, cod-liver oil, a potent source of Vitamin A, was the standard treatment for TB. Vitamin A is essential for normal immune function, and Vitamin A supplementation is used in many countries to reduce mortality in children. Vitamin A deficiency in HIV infected people has been associated with increased mortality in the United States, Haiti, Malawi, and Uganda. This study will determine whether daily Vitamin A supplementation, given concurrently with TB chemotherapy, will reduce mortality in adults with HIV and TB. All study participants will receive standard TB chemotherapy (isoniazid, rifampicin, streptomycin, pyrazinamide) for the first 2 months, followed by isoniazid and ethambutol for the following 6 months. Participants will be randomized to receive either a daily vitamin and mineral supplement or placebo. Participants will be followed for 24 months after study enrollment.

Conditions

Interventions

TypeNameDescription
DRUGmultivitamin

Timeline

Start date
1998-09-01
First posted
2003-04-03
Last updated
2007-09-18

Locations

1 site across 1 country: Malawi

Source: ClinicalTrials.gov record NCT00057434. Inclusion in this directory is not an endorsement.